TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: lowering of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Related Quality of Life - Short Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: paracentesis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Index aneurysm complete or near occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Score (mRS) below or equal to 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching performance scale (RPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal Assays- Oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of LVESVi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative incidence or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target non attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Virological Response Over Time to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Predicted Sustained Virological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety measured using pulse oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety measured using facial image scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health concerns of parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of pre-menopausal patients refusing chemotherapy due to infertility risk
Endpoint domain: Adverse events/effects
Primary endpoint: Change on Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quantitation of Autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in average pain during daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease control (non progression) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spot urinary proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under ROC curve for SV variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative day of normalization of serum bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PT-INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage growth of liver (on basis of CT Volumetry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness in Disorders of Consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peripheral fat tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ventilator-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Induction Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial count reduction in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: N terminal brain natriuretic peptide (NT-pro BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelium-dependent change in forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraocular Pressure (IOP) at 6 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in PGTC seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Sensitivity of the pediatric confusing assessment method (pCAM-ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Correction of lower limb deformities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total Number of Venous Thromboembolic Events (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number Participants With Major Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Scar spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: toxicity associated with reduced intensity therapy and allogeneic SCT
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Depressive Symptoms: Remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Suicide Ideation and Behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Objective Sleep Times
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Subjective Sleep Times
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Acceptability of Acupuncture as a Treatment for Sleep Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs SpO2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health assessment high score >11 on PHQ9 Depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in number and size of adenomas (upper endoscopy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in number and size of adenomas (lower endoscopy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Imaging results for desmoids (CT and MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nasal CPAP failure resulting in endotracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma nicotine concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma nicotine concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma nicotine concentration (AUC0-60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Changes in quality of life of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidative stress marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Pain assessment using McGill Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary tumor dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary tumor perfusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary tumor apparent diffusion coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of obesity awareness and perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of attitudes on obesity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of interactions between patients and HCPs around obesity/overweight
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: ASAS-20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse oximetry measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on a Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-hypopnea index greater than 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toxicity following ALA administration
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to aspirate blood samples without tourniquet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bilateral BIS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in success of the model of care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Yearly HF hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percent change and change from baseline in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate defined as proportion of subjects with a score of 0 or 1 and at least a 2 point improvement from baseline on the IGA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema & telangiectasia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardio-respiratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Auditory brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of seizure-related headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinically detectable neurological ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: subclinically detectable neurological ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in MAS Score in the Primary Targeted Muscle Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Expression level of Met
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression level of Her2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression level of FGFR2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression-free Survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Rehospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Knee Society Function Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With >2mm Wide at the Bone/Cement Interface or a >3 Degree or >3 mm Migration (Shift) of the Component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vision change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological changes (ERG, VEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Clinically Significant Changes in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentrations of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood concentrations of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentrations of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal concentration of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-month progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity assessment of study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Adjudicated double composite of all-cause of death and new myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Adjudicated TIMI significant bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Adverse Events, as Graded per the World Health Organization (WHO) Toxicity Grading Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of antimicrobial resistant E. coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: serum AMH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Age at menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Presence of intracranial arterial stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Solicited Injection Site Reactions After Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited Systemic Reactions After Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in diagnosis and treatment planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient's perception of patient safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time from diagnosis to death for any reason
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of GFR estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-assessment of health condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wrinkle Severity Rating Scale (WSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nighttime Agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum concentration (Cmax) of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum concentration (tmax) of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sleep architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days After Dose 1 (50- to 64-Year Age Cohort)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Systemic Events Within 7 Days After Dose 1 (50- to 64-Year Age Cohort)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Adverse Events (AEs) to Month 2 and Serious AEs (SAEs) to Month 13 (50- to 64-Year Age Cohort)
Endpoint domain: Adverse events/effects
Primary endpoint: Hip extensor and flexor maximal muscle strength during isometric and isokinetic contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip-related self-reported health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants With an Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Levels of C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Levels of Tumor Necrosis Factor-receptor 2 (TNFR2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incident Autoimmune Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of Knee Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in vascular flow parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Biopsies with Tumorous Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in processing speed index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of intraoral injection fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MDS-UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 5-HT1B receptor binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Packed Red Blood Cell Transfusion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of IGA Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of the Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Psychological distress (depression or anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Management of coronary artery disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of GI-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SCORAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Validity of PET/MRI with 68Ga DOTATATE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average change in anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Repigmentation of the vitiligo lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent of Patients Achieving Stable Disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Achieving Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Achieving Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygen saturation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants who are retained in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who are virally suppressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, nonfatal myocardial infarction, or Target-Vessel Revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Change of maximal oxygen uptake during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of Corneal thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes